Gabriele Volpi

Gabriele Volpi

Auto-generated profile, based on publicly available information

Gabriele Volpi

Department of Oncology, Division of Urology, School of Medicine, University of Turin, San Luigi Hospital, Orbassano (Turin), Italy

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in European Urology
Verified
Journal Article
Closed access
FPFrancesco Porpiglia
Francesco Porpiglia
ECEnrico Checcucci
Enrico Checcucci
DADaniele Amparore
Daniele Amparore
FPFederico Piramide
Federico Piramide
GVGabriele Volpi
Gabriele Volpi
AMAlex Mottrie
Alex Mottrie

26 November 2021 in Urology Research and Practice
Verified
Journal Article
Open access
CFCristian Fiori
Cristian Fiori
SCSabrina De Cillis
Sabrina De Cillis
GVGabriele Volpi
Gabriele Volpi
Enrico CheccucciEnrico Checcucci
Enrico Checcucci
GCGiovanni Cattaneo
Giovanni Cattaneo
FPFrancesco Porpiglia
Francesco Porpiglia
In the last few years, new technologies have been developed to treat benign prostatic hyperplasia (BPH) in order to offer valid surgical alternatives to transurethral resection of the prostate with lower complications and hospitalization while maintaining satisfactory functional results. Among these new approaches, transurethral implantation of first- and second-generation temporary implantable nitinol device (TIND and iTIND, respectively) (Medi-TateVR ; Medi-Tate Ltd., Or Akiva, Israel) has been proposed. The aim of this work is to describe the surgical technique and to perform a systematic review of the available literature on follow-up of functional outcomes. A systematic research of the available literature on this topic was performed via Medline, Embase, and Cochrane databases in April 2021. Current evidence regarding the implantation of iTIND to treat BPH-related lower urinary tract symptoms (LUTSs) is still limited. Seven studies have been found. Only one randomized controlled trial has been published reporting short-term follow-up of implantation of iTIND versus sham procedure. All the studies reported that both procedures are safe, effective, and well-tolerated. Moreover, such treatment seems to not affect patient’s sexual and ejaculatory functions. In conclusions, current clinical evidence suggests that temporary implantation of iTIND is a valid option for the minimally invasive surgical treatment of BPH-related LUTS. Further studies are required in order to confirm the functional results, especially over a long-term follow-up. Cite this article as: Fiori C, De Cillis S, Volpi G, et al. iTIND for BPH: Technique and procedural outcomes: A narrative review of current literature. Turk J Urol. 2021; 47(6): 470-481

27 January 2022 in Current Bladder Dysfunction Reports
Verified
Journal Article
Open access
PDF file
SCSabrina De Cillis
Sabrina De Cillis
DADaniele Amparore
Daniele Amparore
GVG. Volpi
G. Volpi
Enrico CheccucciEnrico Checcucci
Enrico Checcucci
GCG. Cattaneo
G. Cattaneo
FPFrancesco Porpiglia
Francesco Porpiglia
Purpose of review: In the last decades, new promising technologies for the treatment of BPH-related lower urinary tract symptoms (LUTS) have been widely experienced in clinical practice, with the aim of offering fewer complications but similar functional outcomes compared with the gold standard transurethral resection of the prostate (TURP). Among these so-called minimally invasive approaches, transurethral implantation of first- and second-generation temporary implantable nitinol device (TIND and iTIND, respectively) (Medi-Tate; Medi-Tate Ltd., Or Akiva, Israel) has been included by the European Association of Urology (EAU) Guidelines as one of the available alternative treatments to TURP. In the present paper, we conducted a systematic review of the current literature on TIND and iTIND implantation focusing on functional outcomes. Medline, Embase, and Cochrane databases were queried for relevant Literature in May 2021. Recent findings: Data regarding the use of temporary implantable nitinol device for BPH are still very limited, with only seven studies currently available in Literature. All the studies report that both TIND and iTIND procedures are safe, effective, and well tolerated. Moreover, such treatments seem to not affect patient’s sexual and ejaculatory functions. Summary: Current clinical evidence suggests that temporary implantation of first- and second-generation temporary implantable nitinol devices are valid options for the minimally invasive surgical treatment of BPH-related LUTS. Further studies are required in order to confirm the functional results, especially over a long-term follow up.



1 September 2019 in European Urology Supplements
Verified
Journal Article
Closed access
DADaniele Amparore
Daniele Amparore
Enrico CheccucciEnrico Checcucci
Enrico Checcucci
MMMartina Manfredi
Martina Manfredi
FPFederico Piramide
Federico Piramide
GVG. Volpi
G. Volpi
FPFrancesco Porpiglia
Francesco Porpiglia